2020-06-15
Parkiet: In the first months of 2020, the number of transactions carried out by PE and VC funds decreased. One of the few actual investments was that of Montis Capital in Biotts – a biotech company. – Biotts is an exception, rather than a rule in these circumstances, as there are virtually no major investments on the market. […]
2020-06-05
Stay tuned. On June 8, our CEO, Paweł Biernat will discuss our unique transdermal carrier and other topics as part of the Health Challenges Congress – HCC Online: Start-ups in medicine (the session will start at 04.15 pm). It is already the fifth edition of the Congress with the main event and all accompanying events entirely held […]
2020-05-06
We have signed a licencing agreement w Balanced Biotech – the American biotech company. Together they will create a revolutionary treatment for breast cancer. The licencing agreement between the companies is valued at several million USD. As of 2018 the market for breast-cancer treatments was valued at 13.4B USD – by 2021 that figure is […]
2020-03-31
My Company: In the business of diagnostics and telemedicine, stakes are high. (…) Although Biotts, a company established in 2018, is already in possession of the product, the licence-selling process takes time, commitment, and global travel. The company’s flagship product: MTC-Y transdermal carrier is a system for delivering active substances into the body through the skin. Depending […]
2020-03-22
We are happy to announce that the Montis Capital fund has invested over 7 mln PLN in the Biotts SA. Biotts – a Wroclaw-based startup – is developing innovative carriers of medical substances as well as drug compositions. Its flagship transdermal carrier can transport particles deep into the skin. The Biotech company has also recently […]
2020-03-10
11.2 million PLN – this is the amount of funding we have received under the “Fast Track” programme of the National Centre for Research and Development (NCBR) to develop antidiabetic therapies (a project worth nearly 15 million PLN). The effectiveness of the Biotts carrier itself in innovative therapies has been confirmed by preclinical studies for […]